Published in J Cell Biochem on June 01, 1996
Escherichia coli maltose-binding protein is uncommonly effective at promoting the solubility of polypeptides to which it is fused. Protein Sci (1999) 5.43
Single amino acid substitutions on the surface of Escherichia coli maltose-binding protein can have a profound impact on the solubility of fusion proteins. Protein Sci (2001) 1.34
Expression and amplification of cyclin genes in human breast cancer. Oncogene (1993) 3.79
Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem (1997) 2.40
Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci U S A (1994) 2.29
Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer (2003) 2.06
Progestin regulation of cellular proliferation. Endocr Rev (1990) 2.04
c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol (1998) 1.97
Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res (2001) 1.77
Prolactin controls mammary gland development via direct and indirect mechanisms. Dev Biol (1999) 1.70
Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol (1993) 1.65
Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res (1999) 1.65
Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res (1983) 1.65
The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer (2009) 1.57
Identification of a human HECT family protein with homology to the Drosophila tumor suppressor gene hyperplastic discs. Oncogene (1998) 1.56
Cloning and characterization of GRB14, a novel member of the GRB7 gene family. J Biol Chem (1996) 1.52
Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur J Cancer Clin Oncol (1983) 1.49
The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol (2012) 1.46
Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene (1994) 1.44
Estrogen regulation of cell cycle progression in breast cancer cells. J Steroid Biochem Mol Biol (1998) 1.42
Overexpression of p21(WAF1/CIP1) is an early event in the development of pancreatic intraepithelial neoplasia. Cancer Res (2001) 1.40
Signaling pathways and structural domains required for phosphorylation of EMS1/cortactin. Cancer Res (1999) 1.39
Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res (1999) 1.39
Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen. Cancer Res (1985) 1.37
Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol (1995) 1.35
A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J Biol Chem (2000) 1.34
Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res (2001) 1.32
Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol (1991) 1.30
High-affinity anti-oestrogen binding site distinct from the oestrogen receptor. Nature (1980) 1.29
Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer. Oncogene (2007) 1.28
Gene regulation by vitamin D3. Crit Rev Eukaryot Gene Expr (1998) 1.28
Estrogen and progestin regulation of cell cycle progression. J Mammary Gland Biol Neoplasia (1998) 1.26
INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res (2000) 1.26
Regulation of the functional interaction between cyclin D1 and the estrogen receptor. Mol Cell Biol (2000) 1.22
Mechanisms of cyclin-dependent kinase inactivation by progestins. Mol Cell Biol (1998) 1.20
A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer (2006) 1.15
Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene (2009) 1.15
Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Br J Cancer (2011) 1.15
Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells. Oncogene (1998) 1.15
A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes. Oncogene (2009) 1.15
All natural DR3-type vitamin D response elements show a similar functionality in vitro. Biochem J (2000) 1.14
A new human breast carcinoma cell line (PMC42) with stem cell characteristics. III. Hormone receptor status and responsiveness. J Natl Cancer Inst (1984) 1.14
Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res (1998) 1.13
Overexpression of the Grb2 gene in human breast cancer cell lines. Oncogene (1994) 1.12
DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer (2008) 1.11
Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes. J Biol Chem (1997) 1.10
Expression and regulation of retinoic acid receptors in human breast cancer cells. Cancer Res (1992) 1.10
Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer (2000) 1.09
Structural determinants of the interaction between the erbB2 receptor and the Src homology 2 domain of Grb7. J Biol Chem (1997) 1.08
Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells. Cancer Res (1983) 1.08
EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Oncogene (1997) 1.08
Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. J Clin Endocrinol Metab (1997) 1.07
Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells. Breast Cancer Res Treat (1994) 1.07
Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin Cancer Res (1997) 1.06
Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. Oncogene (2012) 1.06
EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival. Oncogene (1998) 1.05
Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells. Oncogene (1998) 1.04
Expression of the cyclin-dependent kinase inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer. Int J Cancer (1995) 1.04
Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin Cancer Res (1996) 1.04
Expression of the PEA3 group of ETS-related transcription factors in human breast-cancer cells. Int J Cancer (1997) 1.03
Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780. Int J Cancer (1993) 1.03
Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res (2000) 1.02
Effects of biologically active metabolites of tamoxifen on the proliferation kinetics of MCF-7 human breast cancer cells in vitro. Cancer Res (1983) 1.02
Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin Cancer Res (2001) 1.02
Cell cycle control by steroid hormones. Semin Cancer Biol (1994) 1.02
The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. Br J Cancer (2008) 1.02
Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity. Int J Cancer (1996) 1.00
Mechanisms of oestrogen antagonism by nonsteroidal antioestrogens. Mol Cell Endocrinol (1982) 0.99
Definition of two distinct mechanisms of action of antiestrogens on human breast cancer cell proliferation using hydroxytriphenylethylenes with high affinity for the estrogen receptor. Biochem Biophys Res Commun (1986) 0.99
Up-regulation of the protein tyrosine phosphatase SHP-1 in human breast cancer and correlation with GRB2 expression. Int J Cancer (2000) 0.98
Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle. Cancer Res (1989) 0.98
Central role of VDR conformations for understanding selective actions of vitamin D(3) analogues. Steroids (2001) 0.97
Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. Endocr Relat Cancer (2005) 0.97
Differential apoptotic response of human melanoma cells to 1 alpha,25-dihydroxyvitamin D3 and its analogues. Cell Death Differ (1998) 0.97
Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res (1996) 0.97
Estradiol induction of retinoic acid receptors in human breast cancer cells. Cancer Res (1993) 0.97
Effects of oestrogens on cell proliferation and cell cycle kinetics. A hypothesis on the cell cycle effects of antioestrogens. Eur J Cancer Clin Oncol (1983) 0.97
Functional characterization of cancer-associated Gab1 mutations. Oncogene (2012) 0.97
Factors affecting the sensitivity of T-47D human breast cancer cells to tamoxifen. Cancer Res (1984) 0.96
Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol (2001) 0.96
Microsomal binding sites for nonsteroidal anti-estrogens in MCF 7 human mammary carcinoma cells. Demonstration of high affinity and narrow specificity for basic ether derivatives of triphenylethylene. J Biol Chem (1984) 0.96
Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells. Oncogene (1997) 0.95
Quantitative estimates of cytoplasmic and nuclear oestrogen receptors in chick oviduct. Effect of oestrogen on receptor concentration and subcellular distribution. Eur J Biochem (1976) 0.95
MDA-MB-453, an androgen-responsive human breast carcinoma cell line with high level androgen receptor expression. Eur J Cancer (1994) 0.95
Differential expression of oestrogen regulated genes in breast cancer. Acta Oncol (1995) 0.95
Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells. Mol Cell Biol (2000) 0.95
Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions. Histopathology (2008) 0.94
Genetic instability and the development of steroid hormone insensitivity in cultured T 47D human breast cancer cells. Cancer Res (1988) 0.94
Expression of the androgen receptor and an androgen-responsive protein, apolipoprotein D, in human breast cancer. Br J Cancer (1996) 0.93
Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. Mol Endocrinol (1997) 0.92
Inducible expression of cyclin D1 in T-47D human breast cancer cells is sufficient for Cdk2 activation and pRB hyperphosphorylation. J Cell Biochem (1996) 0.92
Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro. Cancer Res (1987) 0.92